Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q2 2012 Earnings Presentation

13 slides from Questcor Pharmaceuticals's earnings presentation, Jul 30, 2012

  1. Slide 1: Second Quarter 2012 Conference Call

    Second Quarter 2012 Conference Call NASDAQ: QCOR Second Quarter 2012 Conference Call NASDAQ: QCOR Exhibit 99.3

  2. Slide 2: Conference Call Logistics

    • Today’s webcast, accompanying slide presentation and archived replay are available online at • Telephone replay is available by dialing: – U.S.: 877-941-9205 – International: 480-629-9819 • Replay Passcode: 4550797# Conference Call Logistics 2 • Today’s webcast, accompanying slide presentation and

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

  4. Slide 4: Strong Second Quarter Results

    • Record financial performance – 4,710 vials shipped, up 94% YOY – $112.5M in net sales, up 145% YOY – $0.65 GAAP EPS (diluted), up 210% YOY • 314 paid NS scripts • 1,110 paid MS scripts • 96 paid IS scripts Strong Second Quarter Results 4 • Record financial performance – 4,710 vials shipped, up 94%

  5. Slide 5: NS Scripts - Strong Continued Growth

    Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart. NS Scripts-Strong C

  6. Slide 6: MS Scripts - Record of Consistent Growth

    MS Scripts-Record of Consistent Growth 6 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descripti

  7. Slide 7: Monthly MS Scripts History

    Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the con

  8. Slide 8: Shipped Vials

    Shipped Vials Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-141 Q3-11 Q4-141 Q1-12 Q2-12 =@Shipped Vials ( QUESTCOR’

  9. Slide 9: Understanding Acthar: science of how it works and clinical use

    • Understanding the biological properties of Acthar – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory • On-label indications – Proteinuria in NS, MS flares, Lupus • New indications – Nephrology (eg, diabetic nephropathy) – Indications with autoimmune/inflam

  10. Slide 10: Understanding Acthar: clinical use

    • Clinical use of Acthar – Nonclinical research – Clinical research • On-label indications – Proteinuria in nephrotic syndrome (NS), multiple sclerosis (MS) flares, infantile spasms, lupus • Off-label indications – Diabetic nephropathy, traumatic brain injury, autism, MS maintenance treatment Academ

  11. Slide 11: Q2-2012 Financial Results

    Q2 – 2012 Q2 – 2011 Q2-2012 Financial Results Record Net Sales (up 145%) and Solid Earnings (EPS up 210%) 11 Net Sales ($M) $112.5 $46.0 Gross Margin 94% 94% Operating Income ($M) $61.0 $20.4 Fully Diluted, GAAP EPS $0.65 $0.21 • Second quarter vials shipped: 4,710 • Second quarter cash flow from op

  12. Slide 12: Questcor is Cash Flow Positive

    Questcor is Cash Flow Positive Debt-free balance sheet *After return of $264 million of cash to shareholders through share repurchases. 12 07/23/12 Cash / ST Investments $129M* Accounts Receivable $54M *After return of $264 million of cash to shareholders through share repurchases.

  13. Slide 13: Investment Highlights

    Investment Highlights 13 Acthar has sustainable competitive advantages-without FDA approval risk Acthar is approved for 19 indications-many in large markets with sizable unmet need Sales in NS and MS are growing rapidly, yet market penetration is low Developing new vertical market - Rheumatology Hig

Questcor Pharmaceuticals — Q2 2012 Earnings Presentation on 6ix